Article Text

other Versions

Download PDFPDF
Monoclonal antibodies for the early treatment of paediatric COVID-19 patients: a tangible contribution from hospital pharmacists in the lack of evidence
  1. Sabrina Trivellato1,
  2. Daniele Mengato1,
  3. Daniele Donà2,
  4. Marica De Pieri2,
  5. Francesca Venturini1
  1. 1Hospital Pharmacy Department, Padua University Hospital, Padova, Italy
  2. 2Department for Women's and Children's Health, Division of Pediatric Infectious Diseases, Padua University Hospital, Padova, Italy
  1. Correspondence to Dr Daniele Mengato, Hospital Pharmacy, Padua University Hospital, Padova 35121, Italy; daniele.mengato{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Unlike adults, most paediatric patients experience mild severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, showing favourable outcomes and extremely low hospitalisation rates.1 However, if we consider frail patients, the risk of developing a severe coronavirus disease (COVID-19) increases to even life-threatening clinical scenarios.2

Due to their immunosuppressive status, transplant recipients and onco-haematological children represent a restricted but vulnerable cohort of patients exposed to high-risk outcomes.2

Currently available therapies approved by the European Medicines Agency (EMA) for early stages of infection in patients at high risk of developing a severe form of the disease include neutralising monoclonal antibodies (mAbs) and antiviral agents. However, only mAbs have been currently approved for paediatric patients …

View Full Text


  • Contributors ST and DM wrote the paper and collected the necessary data. DD and MDP revised the paper. FV supervised the whole process and promoted the project.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.